

Response

2  
The Department may, at its discretion, publish part or all of the information provided in your submission on the Department's website or in related documents. If information from your submission is published, the Department may identify you and/or your organisation as the author of the submission. All personal contact details will be removed prior to publishing.

Yes, I consent to my identified submission being published

3

What is your name?

Gabrielle Reppen

7

Please select the type of individual(s) or organisation(s) you represent. Please select all that apply. - Selected Choice

Pharmaceutical / Medical technology company

8.1

What is the name of your organisation? - My organisation is called: - Text

Eli Lilly Australia Pty Ltd

9

Are you making feedback on behalf of your organisation?

Your organisation

13

Please select which chapter/s you would like to provide feedback on. You may provide feedback on as many or few chapters as you wish.

1. Transparency, communication, and stakeholder involvement in HTA,2. Health technology funding and assessment pathways,3. Methods for HTA for Australian government subsidy (technical methods),4. Health technology funding and purchasing approaches and managing uncertainty,5. Futureproofing Australia's systems and processes

14

Please select the topics within the chapter(s) you would like to provide feedback on. 1. Transparency, communication and stakeholder involvement in HTA

1.1. Transparency and communication of HTA pathways, processes and decisions,1.2. Consumer, clinician and other stakeholder engagement and consideration in HTA,1.3. First Nations people involvement and consideration in HTA,1.4. State and territory government collaboration in HTA

15

Please select the topics within the chapter(s) you would like to provide feedback on. 2. Health technology funding and assessment pathways

2.1. Streamlining and aligning HTA pathways and advisory committees,2.2. Proportionate appraisal pathways

16

Please select the topics within the chapter(s) you would like to provide feedback on. 3. Methods for HTA for Australian government subsidy (technical methods)

3.1. Determination of the Population, Intervention, Comparator, Outcome,3.2. Clinical Evaluation Methods,3.3. Economic evaluation

17

Please select the topics within the chapter(s) you would like to provide feedback on. 4. Health Technology funding and purchasing mechanisms and decisions

4.1. Approaches to funding or purchasing new health technologies,4.2. Approaches to incentivise development of products that address antimicrobial resistance (AMR),4.3. Understanding the performance of health technologies in practice

18

Please select the topics within the chapter(s) you would like to provide feedback on. 5. Futureproofing our systems and processes

5.1. Proactively addressing areas of unmet clinical need and gaps in the PBS,5.2. Establishment of horizon scanning programs to address specific informational needs within HTA and the health system,5.3. Consideration of environmental impacts in the HTA,5.4. Mechanisms for continuous review and improvement,5.5. Capacity and capability of the HTA system,5.6. Strengthen international partnerships and work-sharing

21

Taking all Options within this section: 1.1. Transparency, communication and stakeholder involvement in HTA into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Mostly address the issue(s)

22

If you would like to expand on your answer above you can do so below:

N/A

23.1

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Publish plain language summaries

Positive

23.2

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Improvements to the HTA webpage including development of a dashboard

Don't know

25

If you would like to expand on your answer above you can do so below -Publish plain language summaries

N/A

26

If you would like to expand on your answer above you can do so below -Improvements to the HTA webpage including development of a dashboard

Effectiveness of dashboard dependent on measures included and accuracy.

27

Taking all Options within this section: 1.2. Consumer, clinician and other stakeholder engagement and consideration in HTA into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Address little or none of the issue(s)

28

If you would like to expand on your answer above you can do so below:

Research commissioned by Lilly shows that medical specialists believe Australia would benefit from faster, more efficient medicine funding processes, easing of eligibility criteria for already reimbursed therapies, greater clinician input to reimbursement decision-making, and Government efforts to shore up supply of reimbursed medicines. More than 70% of clinicians surveyed would like greater input to decision-making about which medicines are listed on the PBS and eligible patient populations. These findings were detailed in Lilly's Consultation 1 submission.

29.1

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Develop an engagement framework

Positive

29.2

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Strengthen consumer evidence

Positive

31

If you would like to expand on your answer above you can do so below -Develop an engagement framework

N/A

32

If you would like to expand on your answer above you can do so below -Strengthen consumer evidence

N/A

33

Taking all Options within this section: 1.3. First Nations people involvement and consideration in HTA into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Mostly address the issue(s)

34

If you would like to expand on your answer above you can do so below:

N/A

35.1

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - First Nations peoples partnership in decision making

Very positive

35.2

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Dedicated resource for HTA submissions and education

Very positive

37

If you would like to expand on your answer above you can do so below -First Nations peoples partnership in decision making

N/A

38

If you would like to expand on your answer above you can do so below -Dedicated resource for HTA submissions and education

N/A

39

Taking all Options within this section: 1.4. State and territory government collaboration in HTA into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Address little or none of the issue(s)

40

If you would like to expand on your answer above you can do so below:

The issue is complex and requires a comprehensive solution, which is not provided in the Options Paper.

41.1

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Development of central standardised data sharing system for utilisation and outcome data

Very positive

41.2

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Increase opportunities for consultation and work sharing

Don't know

41.3

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Health technologies that are jointly funded by the Commonwealth and state and territory governments (such as high cost, Highly Specialised Therapies (HSTs) delivered to public hospital inpatients)

Neutral

43

If you would like to expand on your answer above you can do so below -Development of central standardised data sharing system for utilisation and outcome data

N/A

44

If you would like to expand on your answer above you can do so below -Increase opportunities for consultation and work sharing

N/A

45

If you would like to expand on your answer above you can do so below -Health technologies that are jointly funded by the Commonwealth and state and territory governments (such as high cost, Highly Specialised Therapies (HSTs) delivered to public hospital inpatients)

N/A

46

Taking all Options within this section: 2.1. Streamlining and aligning HTA pathways and advisory committees into account.

Overall, to what extent could the options (if implemented) address the issues that relate to them?

Mostly address the issue(s)

47

If you would like to expand on your answer above you can do so below:

Must ensure appropriate expertise available and sufficient capacity.

48.1

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Pathway for drugs for ultra-rare diseases (Life Saving Drugs Program (LSDP))

Neutral

48.2

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Vaccine pathway

Neutral

48.3

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Expanding role of PBAC

Positive

48.4

If implemented, overall would these Options have a positive or negative impact on you (/your organisation)? - Unified HTA pathway for all health technologies with Commonwealth funding

Positive

50

Pathway for drugs for ultra-rare diseases (Life Saving Drugs Program (LSDP))

N/A